Who is sponsoring NCT03821727?

NCT03821727 is sponsored by CANDONI ANNA.

What drugs are being tested in NCT03821727?

Interventions in NCT03821727: Hematopoietic Stem Cell Transplantation.

What condition does NCT03821727 study?

NCT03821727 studies Philadelphia Positive Acute Lymphoblastic Leukemia, SCT.

Is NCT03821727 still recruiting?

NCT03821727 is currently completed. Last updated 30 January 2019.

Last reviewed 2019-01-30 · How we verify

NCT03821727

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SCT in Ph Positive Acute Lymphoblastic Leukemia

Completed Last updated 30 January 2019

What this trial tests

trial testing Hematopoietic Stem Cell Transplantation in Philadelphia Positive Acute Lymphoblastic Leukemia in 441 participants. Completed in 30 June 2018.

Timeline

26 October 2016

Primary endpoint
31 December 2017

30 June 2018

Quick facts

Lead sponsor	CANDONI ANNA
Status	Completed
Study type	OBSERVATIONAL
Enrollment	441
Start date	26 October 2016
Primary completion	31 December 2017
Estimated completion	30 June 2018
Sites	2 locations across Italy

Drugs / interventions tested

Hematopoietic Stem Cell Transplantation — full drug profile →

Conditions studied

Philadelphia Positive Acute Lymphoblastic Leukemia — all drugs for Philadelphia Positive Acute Lymphoblastic Leukemia →
SCT — all drugs for SCT →

Sponsor

CANDONI ANNA

Who can join

18 and older, any sex, with Philadelphia Positive Acute Lymphoblastic Leukemia or SCT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study includes a registry-based, nationwide analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a Tyrosine Kinase Inhibitors (TKI)-based treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

47° Congress of the Italian Society of Hematology Rome, Italy, October 7-9, 2019
· 2019

Verify or expand the search:

Other trials of Hematopoietic Stem Cell Transplantation

Trials testing the same drug.

NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT00630253 — Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia · Phase 1, PHASE2 · completed

Other recruiting trials for Philadelphia Positive Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT06481228 — Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL · NA · recruiting
NCT04260022 — Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03821727 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CANDONI ANNA
Last refreshed: 30 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03821727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing